Summary:
A one-year placebo-controlled study evaluating the efficacy and safety of the house dust mite sublingual allergen immunotherapy tablet (SCH 900237/MK 8237) in children and adult subjects with house dust mite-induced Allergicrhinitis/Rhinoconjunctivitis with or without Asthma.
Qualified Participants Must:
• Have a known dust allergy
Qualified Participants May Receive:
Compensation for their time and travel